Literature DB >> 15693101

Soluble intercellular adhesion molecule-1 and E-selectin as markers of disease activity and endothelial activation in juvenile idiopathic arthritis.

Bradley J Bloom1, Sarah M Nelson, Daniel Eisenberg, Anthony J Alario.   

Abstract

OBJECTIVE: To determine whether soluble forms of the adhesion molecules intercellular adhesion molecule-1 (ICAM-1) and E-selectin correlate with clinical measures or other markers of endothelial activation in children with juvenile idiopathic arthritis (JIA) over time.
METHODS: A total of 28 children with JIA were studied every 3 months over 2 years. At each interval, serum was tested for soluble (s)ICAM-1 and sE-selectin, plasma for fibrin d-dimer and von Willebrand factor (vWF), and the following clinical variables were recorded: erythrocyte sedimentation rate (ESR), physician and parent global assessments, swollen and limited joint counts, and functional assessment by Childhood Health Assessment Questionnaire. Concentrations of the adhesion molecules were also determined once in 30 age matched healthy children.
RESULTS: Among all JIA subtypes, baseline sICAM-1 was elevated compared to controls; sE-selectin was higher in patients with systemic disease compared to other subtypes and controls. sE-selectin correlated with ESR, but there were no other correlations between concentrations of either adhesion molecule or any other clinical variables or vWF antigen. sICAM-1 was higher in those with elevated compared to normal d-dimer. There were no differences between mean sICAM-1 and sE-selectin before or during disease flare or improvement periods, except for an increase in sICAM-1 with flares in patients with systemic disease.
CONCLUSION: sICAM-1 is elevated in children with active JIA. sE-selectin is only elevated in children with active systemic disease. Although some relationships were found between the adhesion molecules and other variables, they did not correlate with most variables, and did not parallel the disease course. Thus, we cannot recommend the routine use of these molecules as clinical biomarkers of disease activity. This study confirms that endothelial activation is key to the pathogenesis of JIA, especially in the systemic subtype.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15693101

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  7 in total

1.  Release of soluble E-selectin from activated endothelial cells upon apoptosis.

Authors:  Elizabeth O Harrington; Tihomir Stefanec; Julie Newton; Sharon Rounds
Journal:  Lung       Date:  2006 Sep-Oct       Impact factor: 2.584

2.  Plasma levels of D-dimer in a 5-year-old girl with systemic juvenile idiopathic arthritis: A case report and literature review.

Authors:  Qiang Xu; Chang-Song Lin
Journal:  Exp Ther Med       Date:  2016-01-20       Impact factor: 2.447

3.  Prediction of residual valvular lesions in rheumatic heart disease: role of adhesion molecules.

Authors:  Mona Hafez; Sohier Yahia; Waleed Eldars; Heba Eldegla; Mohamed Matter; Gehan Attia; Samia Hawas
Journal:  Pediatr Cardiol       Date:  2012-09-18       Impact factor: 1.655

4.  Anti-endothelial cell antibodies are prevalent in juvenile idiopathic arthritis: implications for clinical disease course and pathogenesis.

Authors:  Bradley J Bloom; Mieko Toyoda; Anna Petrosian; Stanley Jordan
Journal:  Rheumatol Int       Date:  2006-12-13       Impact factor: 3.580

Review 5.  Review of biomarkers in systemic juvenile idiopathic arthritis: helpful tools or just playing tricks?

Authors:  Faekah Gohar; Christoph Kessel; Miha Lavric; Dirk Holzinger; Dirk Foell
Journal:  Arthritis Res Ther       Date:  2016-07-13       Impact factor: 5.156

6.  A Cross-Tissue Transcriptome-Wide Association Study Identifies Novel Susceptibility Genes for Juvenile Idiopathic Arthritis in Asia and Europe.

Authors:  Jiawen Xu; Jun Ma; Yi Zeng; Haibo Si; Yuangang Wu; Shaoyun Zhang; Bin Shen
Journal:  Front Immunol       Date:  2022-07-28       Impact factor: 8.786

7.  Combined anti-tumor necrosis factor-α therapy and DMARD therapy in rheumatoid arthritis patients reduces inflammatory gene expression in whole blood compared to DMARD therapy alone.

Authors:  Carl K Edwards; Julie S Green; Hans-Dieter Volk; Michael Schiff; Brian L Kotzin; Hiroaki Mitsuya; Tatsuya Kawaguchi; Ken-Mei Sakata; John Cheronis; David Trollinger; Danute Bankaitis-Davis; Charles A Dinarello; David A Norris; Michael P Bevilacqua; Mayumi Fujita; Gerd-Rudiger Burmester
Journal:  Front Immunol       Date:  2012-12-04       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.